Novel approaches to advanced breast cancer: Bevacizumab and lapatinib

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 5, Issue 3, 2007, Pages 314-323

  Mayer, Erica L ^a   Lin, Nancy U ^a   Burstein, Harold J ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis inhibitor; Bevacizumab; Biologic therapy; HER2; Lapatinib; Metastatic breast cancer; Vascular endothelial growth factor

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; ANTHRACYCLINE; AXITINIB; BEVACIZUMAB; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; GEFITINIB; GW 592106; LAPATINIB; LETROZOLE; METHOTREXATE; NAVELBINE; PACLITAXEL; PAZOPANIB; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; VANDETANIB; VATALANIB;

ANGIOGENESIS; BLEEDING; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG DIFFUSION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; FATIGUE; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; LOW DRUG DOSE; MONOTHERAPY; NAUSEA; PNEUMONIA; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; SIDE EFFECT; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT;

EID: 33947544435     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2007.0026     Document Type: Review

References (73)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186.
2. Rosen LS. VEGF-targeted therapy: therapeutic potential and recent advances. Oncologist 2005;10:382-391.
3. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029-1039.
4. Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995;26:86-91.
5. Guidi AJ, Fischer L, Harris JR, Schnitt SJ. Microvessel density and distribution in ductal carcinoma in situ of the breast. J Natl Cancer Inst 1994;86:614-619.
6. Guidi AJ, Schnitt SJ, Fischer L, et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer 1997;80:1945-1953.
7. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-1887.
8. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
9. Linderholm BK, Lindh R, Beckman L, et al. Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers. Clin Breast Cancer 2003;4:340-347.
10. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-147.
11. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
12. Sandler A, Gray R, Brahmer J, et al. Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial - E4599 [abstract]. J Clin Oncol 2005;23(Suppl 16):Abstract LBA4.
13. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-434.
14. Miller K, Wang M, Gralow J, et al. E2100: a randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer [abstract]. J Clin Oncol 2005;23(suppl 1): Abstract 7001.
15. Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003;30(suppl 16):117-124.
16. Burstein H, Parker LM, Savoie J, et al. Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory advanced breast cancer. Breast Cancer Res Treat 2002;76(suppl 1):S115.
17. Ramaswamy B, Elias AD, Kelbick NT, et al. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res 2006;12:3124-3129.
18. Burstein HJ, Spigel D, Kindsvogel K, et al. Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study. Breast Cancer Res Treat 2005;94(supp 1):S6.
19. Traina TA, Rugo H, Caravelli J, et al. Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC) [abstract]. J Clin Oncol 2006;24 (suppl 1): Abstract 3050.
20. Pegram M, Yeon C, Ku N, et al. Phase I combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER2 proto-oncogene and vascular endothelial growth factor (VEGF). Breast Cancer Res Treat 2004;88(supp 1):S124-125.
21. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-799.
22. Miller KD, Wang M, Gralow J, et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 2005;94:S6.
23. Overmoyer B, Silverman P, Leeming R, et al. Phase II trial of neoadjuvant docetaxel with or without bevacizumab in patients with locally advanced breast cancer. Breast Cancer Res Treat 2004;88 (suppl 1):S106.
24. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006;24:769-777.
25. Motzer RJ, Hutson TE, Tomczak P, et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol 2006;24(suppl 1): Abstract LBA3.
26. Demetri GD, van Oosterom AT, Blackstein M, et al. Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST [abstract]. J Clin Oncol 2005;23(suppl 1): Abstract 4000.
27. Escudier B, Szczylik C, Eisen T, et al. Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) [abstract]. J Clin Oncol 2005;23(suppl 1): Abstract 4510.
28. Miller KD, Burstein HJ, Elias AD, et al. Phase II study of SU11248, a multitargeted tyrosine kinase inhibitor (TKI) in patients (pts) with previously treated metastatic breast cancer (MBC). Breast Cancer Res Treat 2005;94:S61.
29. Moreno-Aspitia A, Hillman DW, Wiesenfeld M, et al. BAY 43-9006 as single oral agent in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane [abstract]. J Clin Oncol 2006;24(suppl 1): Abstract 577.
30. Tsuda H, Takarabe T, Hasegawa T, et al. Myoepithelial differentiation in high-grade invasive ductal carcinomas with large central acellular zones. Hum Pathol 1999;30:1134-1139.
31. Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132-1139.
32. Akiyama T, Sudo C, Ogawara H, et al. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986;232:1644-1646.
33. Muller WJ, Sinn E, Pattengale PK, et al. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated e-neu oncogene. Cell 1988;54:105-115.
34. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic bteast cancer. J Clin Oncol 2002;20:719-726.
35. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
36. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684.
37. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-820.
38. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672.
39. th Annual San Antonio Breast Cancer Symposium. December 8-11, 2005; San Antonio, Texas.
40. Rusnak DW, Lackey K, Affleck K. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW572016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001;1:85-94.
41. Xia W, Mullin RJ, Keith BR, et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002;21:6255-6263.
42. Wood ER, Truesdale AT, McDonald OB, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004;64:6652-6659.
43. Zhou H, Kim YS, Peletier A, et al. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int J Radiat Oncol Biol Phys 2004;58:344-352.
44. Xia W, Liu LH, Ho P, et al. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation wirh ErhB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 2004;23:646-653.
45. Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006;66:1630-1639.
46. Kim TE, Murren JR. Lapatinib ditosylate GlaxoSmithKline. Drugs 2003;6:886-893.
47. Bence AK, Anderson EB, Halepota MA, et al. Phase 1 pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Invest New Drugs 2005;23:39-49.
48. Versola MJ, Burris HA III, Jones S, et al. Clinical activity of GW572016 in EGF10003 in patients with solid tumors [abstract]. J Clin Oncol 2004;22(suppl 1): Abstract 3047.
49. Burris HA III, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study ot lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005;23:5305-5313.
50. Blackwell K, Kaplan EH, Franco SX, et al. A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer [abstract]. J Clin Oncol 2004:22 (suppl 1): Abstract 3006.
51. Blackwell K, Burstein HJ, Pegram M, et al. Determining relevant biomarkers from tissue and serum that may predict response ro single agent lapatinib in trastuzumab-refractory metastatic breast cancer [abstract]. J Clin Oncol 2005;23(suppl 1): Abstract 3004.
52. Gomez HL, Chavez MA, Doval DC, et al. A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH-positive advanced ot metastatic breast cancer [abstract]. J Clin Oncol 2005;23(suppl 1): Abstract 3046.
53. Spector NL, Blackwell K, Hurley J, et al. EGF103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): clinical activity and biologic predictors of response [abstract]. J Clin Oncol 2006;24(suppl 1): Abstract 502.
54. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance inpatients. Cancer Cell 2004;6:117-127.
55. Gomez HL, Doval DC, Chavez MA, et al. Biomarker results from a phase II randomized study of lapatinib as first-line treatment for patients with ErbB2 FISH-amplified advanced or metastatic breast cancer. Presented at the 28th Annual San Antonio Breast Cancer Symposium; December 8-11, 2005; San Antonio, Texas. Abstract 1071.
56. Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer [abstract]. J Clin Oncol 2006;24(suppl 1): Abstract 503.
57. Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003;97:2972-2977.
58. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004;22:3608-3617.
59. Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol 2000;18:2349-2351.
60. Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer 2002;95:1592-1600.
61. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:7811-7819.
62. Perez EA, Byrne J A, HAmmond IW, et al. Results of an analysis of cardiac function in 2,812 patients treated with lapatinib [abstract]. J Clin Oncol 2006;24(suppl 1): Abstract 583.
63. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-2743.
64. Stemmler HJ, Kahlert S, Siekiera W, et al. Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC). Onkologie 2005;28:582-586.
65. Jones SF, Hainsworth JD, Spigel DR, et al. A phase I study of the dual kinase inhibitor GW572016 in combination with paclitaxel (EGF10009) [abstract]. J Clin Oncol 2004;22(suppl 1): Abstract 2083.
66. Chu Q, Goldstein L, Murray N, et al. A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with letrozole in cancer patients [abstract]. J Clin Oncol 2005;23(suppl 1): Abstract 3001.
67. Storniolo AM, Burris HA III, Pegram M, et al. A phase I, open-label study of lapatinib (GW572016) plus trastuzumab: a clinically active regimen [abstract]. J Clin Oncol 2005;23(suppl 1): Abstract 559.
68. Chu I, Blackwell K, Chen S, et al. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 2005;65:18-25.
69. Osborne CK, Shou J, Massarweh S, et al. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005;11:865s-870s.
70. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 - and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19:3808-3816.
71. De Laurentiis M, Arpino G, Massarelli E, er al. A meta-analysis on rhe interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 2005;11:4741-4748.
72. Xia W, Gerard CM, Liu L, et al. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 2005;24:6213-6221.
73. Carlson RW, Anderson BO, Burstein HJ, et al. The NCCN Breast Cancer Guidelines, version 1, 2007. Available at: www.nccn.org.